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Abstract
Recently, it was shown that the exposure to the potent hop phytoestrogen 8-prenylnaringenin (8-PN) depends on intestinal
bacterial activation of isoxanthohumol (IX), but this occurs in only one-third of tested individuals. As the butyrate-producing
Eubacterium limosum can produce 8-PN from IX, a probiotic strategy was applied to investigate whether 8-PN production
could be increased in low 8-PN producers, thus balancing phytoestrogen exposure. Using fecal samples from high (Hop1)
and low (Hop2) 8-PN–producing individuals, a Hop1 and Hop2 dynamic intestinal model was developed. In parallel, Hop
1 and Hop 2 human microbiota-associated rats were developed, germ-free (GF) rats acting as negative controls. IX and
then IX 1 E. limosum were administered in the intestinal model and to the rats, and changes in 8-PN production and
exposure were assessed. After dosing IX, 80% was converted into 8-PN in the Hop1model and highest 8-PN production,
plasma concentrations, and urinary and fecal excretion occurred in the Hop 1 rats. Administration of the bacterium
triggered 8-PN production in the GF rats and increased 8-PN production in the Hop2model and Hop2 rats. 8-PN excretion
was similar in the feces (294.1 6 132.2 nmol/d) and urine (8.5 6 1.1 nmol/d ) of all rats (n ¼ 18). In addition, butyrate
production increased in all rats. In conclusion, intestinal microbiota determined 8-PN production and exposure after IX
intake. Moreover, E. limosum administration increased 8-PN production in low producers, resulting in similar 8-PN
production in all rats. J. Nutr. 138: 1310–1316, 2008.
Introduction
Hops have been identified as a source of the potent phytoestrogen
8-prenylnaringenin (8-PN)8 (1) and hop extracts are used to
relieve menopausal complaints (2). Previously, we have shown
that the final level of 8-PN does not depend on the presence of
8-PN itself in hop products but rather on the combined presence
in the plant of a more abundant precursor, isoxanthohumol (IX),
and the metabolic potential of the intestinal microbiota (3,4).
Intestinal bacteria were shown to demethylate IX into 8-PN,
thereby increasing the 8-PN exposure 10-fold. As IX is the main
prenylflavonoid present in both beer and hop extracts (5),
prenylflavonoids are now considered as a 3rd important group
of phytoestrogens relevant to human nutrition, in addition to
isoflavones and lignans (6).
However, due to interindividual intestinal variability, only
about one-third of the individuals were found to be capable of
efficiently performing this transformation, leading to large
differences in 8-PN exposure after consumption of hops (7).
Eubacterium limosum is an anaerobic Gram-positive rod and is
present in the colon of most humans (8). Over the last few years,
this bacterium has gained increased attention because of its
beneficial effects in inflammatory bowel disease, possibly at-
tributed to its butyrate-producing capacity (9,10). Butyrate is
known to modulate epithelial cell proliferation and has protective
effects on inflammatory bowel disease (11), but oral butyrate
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treatment did not prove efficient because of the difficulty of
delivering butyrate to the colon (12). Therefore, a good al-
ternative would be to administer butyrate-producing probiotics,
such as E. limosum (13).
Moreover, this bacterium was recently shown to efficiently
activate IX into 8-PN (4). Because of this ability and its probiotic
potential, we hypothesized that the combined uptake of E.
limosum and hop extracts could lead to increased health effects
by improving the colonic environment (e.g. bacterial butyrate
production) and by the production of 8-PN in people who lack
the appropriate intestinal metabolic potential. This hypothesis
was investigated in vitro in a dynamic model of the intestine,
followed by an in vivo trial with germ-free (GF) and human
microbiota-associated (HMA) rats.
Materials and Methods
Chemicals. The isolation of xanthohumol, isomerization into IX, and
chemical 8-PN synthesis were performed as described earlier by
Possemiers et al. (4). Stock solutions of IX and 8-PN were prepared in
ethanol (5 g/L).
Preparation of the E. limosum inocula. E. limosum strain LMG
P-23546 (4) was grown anaerobically at 37C in brain heart infusion
broth (Oxoid) with 0.5 g/L L-cysteine HCl, 5 g/L yeast extract, and 5 mg/L
haemin. After growth to a concentration of approximately log 12
colony-forming units/L, 15 mL of the growth medium were centrifuged
(15,000 3 g; 15 min) and resuspended in 15 mL saline (0.9 g/L NaCl).
This suspension was immediately used for administration of the bac-
terium to the simulator of the human intestinal microbial ecosystem
(SHIME) or to the rats.
Identification of high and low 8-PN–producing human fecal
microbiota. Twelve volunteers delivered a fecal sample for incubation
purposes. The samples were prepared immediately and incubated with
25 mg/L IX (4). Based on these results, high (Hop 1) and low (Hop 2)
8-PN–producing individuals were selected. Their 8-PN production status
was confirmed by administering a capsule containing 5.596 0.97 mg IX
for 4 consecutive days and by quantifying the relative 8-PN excretion on
d 4 in a 24-h urine sample. To avoid background prenylflavonoids,
subjects were asked to refrain from consuming hop-containing products
from 4 d before to the end of the intervention. The high and low 8-PN
producers were asked to deliver fecal samples for inoculating the SHIME
and GF rats.
SHIME experiments. The reactor setup was adapted from the SHIME
(14), consisting of 5 successive reactors, simulating the stomach, small
intestine, and ascending, transverse, and descending colon. The micro-
bial community in the last 3 reactors is derived from a selected fresh fecal
sample. Reactor setup, inoculum preparation, and reactor feed compo-
sition have been previously described (15). For this experiment, a
TWINSHIME setup was developed by operating 2 systems in parallel.
The systems were inoculated with a fecal sample from the identified high
and low 8-PN producers and designated respectively as Hop1 and Hop
– compartments. After the reactor start up and a 3-wk stabilization period
(15), 25 mg/L IX was administered for 4 wk to the SHIME feed entering
both systems (Expt. 1). After 2 wk, log 9 E. limosum was administered
daily to the ascending colon part of both systems for 2 wk (Expt. 2).
Rat experiments. GF 5- to 7-wk-old male and female F344 rats were
obtained from our GF rodent breeding facilities. They were randomly
separated into 3 groups of 12 rats (6 males and 6 females), housed in
3 sterile isolators (Ingenia) that were maintained in controlled condi-
tions of light (0700–1900 h), temperature (20–22C), and humidity
(45–55%). Within each isolator, male and female rats were kept
separately in groups of 3 in standard macrolon cages containing a bed
of wood shavings. Throughout the study, they were given free access to
autoclaved tap water and a pelleted semipurified diet (Table 1) (16)
commercially prepared by SAFE and sterilized by g-irradiation at 45
kGy (IBA Mediris). One group of rats remained GF and rats from the 2
other groups were colonized with the fecal microbiota of either the Hop
1 or Hop 2, using gavage with freshly prepared fecal suspensions (16).
The experiment started after a 3-wk acclimatization phase to permit
establishment of the microbiota and adaptation of the rats. All pro-
cedures were carried out according to European guidelines for the care
and use of laboratory animals and with permission 78–58 of the French
Veterinary Services.
Two separate experiments were designed. The purpose of Expt. 1 was
to assess the formation of 8-PN from IX in GF, Hop –, and Hop 1 rats.
Therefore, all rats were gavaged every morning for 4 d with IX (2 mg/kg
body weight) dissolved in ethanol:propylene glycol (50:50, v:v). Rats
were housed in metabolism cages during the last 2 d of the dosing period
to collect 24-h urine and fecal outputs (17) for IX and 8-PN analysis.
Fresh feces were also collected before and at the end of the dosing period
for microbiota analysis. On the day following the last gavage, one-half of
the rats of each group (n ¼ 6, 3 males and 3 females) were anesthetized
with isoflurane (Aerrane, Baxter) and blood was collected from the
inferior vena cava in heparinized tubes to prepare plasma for IX and
8-PN analysis. Rats were killed by section of the abdominal aorta and liver,
kidneys, brain, and uterus in females were collected for IX and 8-PN
analysis. Cecal and colonic contents were collected for incubation
experiments with IX and a cecal content sample was stored for butyrate
analysis. All samples were stored at 280C until analyses.
After a 3-wk washout period, the remaining 6 rats of each group
entered into Expt. 2. This was designed to assess the formation of 8-PN
from IX in GF, Hop –, and Hop 1 rats supplemented with E. limosum.
Therefore, all rats were gavaged every day for 4 d with the IX solution
and for 6 d with E. limosum (109 colony-forming units per rat). E.
limosum administration started 2 d prior to IX dosage to ensure a steady-
state presence of the bacterium in the rat intestine. Furthermore, IX was
given in the morning and E. limosum in the afternoon to avoid a possible
direct interaction during the bolus transit. Biological fluids and organs
were collected as in Expt. 1.
Incubation experiments with the rat intestinal contents. The cecal
and colonic contents were diluted to 10% (v:v) in supplemented brain
heart infusion broth, homogenized with an Ultra-Turrax blender, and
incubated anaerobically at 37C for 72 h.














1 Analytical compounds of dry matter were: crude proteins, 18%; crude fat, 8%; ash,
6%; carbohydrates, 68% (energy 19.33 MJ/kg; Eurofins Scientific Analytics).
2 Nurish 1500 from DuPont Protein Technologies.
3 Supplied the following (to provide g/kg diet): Ca, 2.11; P, 5.46; Na, 2.74; K, 3.67; Mg,
1.02; Fe, 0.10; Cu, 0.09; Mn, 0.55; Zn, 0.31; I, 0.0043; Co, 0.0007.
4 Supplied the following (to provide mg/kg diet, except as noted): all-trans retinol
acetate, 6.88; cholecalciferol, 62.5 mg; all-rac-a-tocopheryl acetate, 175; menadione
sodium bisulfite, 35.2; thiamin hydrochloride, 22.4; riboflavin, 15; nicotinic acid, 100;
calcium DL-pantothenate, 7.5; pyridoxine hydrochloride, 12.15; folic acid, 5; D-biotin, 0.3;
cyanocobalamin, 0.05; ascorbic acid, 0.8; choline chloride, 1.56 g; myo-inositol, 150.
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Processing of SHIME samples and rat biological fluids and
tissues. Sampling and prenylflavonoid extraction from the colon com-
partments of the SHIME systems were carried out as described pre-
viously (3).
Urine was centrifuged (8000 3 g; 5 min at 4C) to remove
particulates and fecal samples were lyophilized and ground. To 1 mL
urine supernatant, 1 mL sodium acetate buffer (0.1 mol/L, pH 5.0) and
50 mL b-glucuronidase/arylsulfatase (10/0.33 MU/L, Sigma-Aldrich)
were added. Similarly, to 500mg feces, 9.5 mL sodium acetate buffer and
250 mL b-glucuronidase/arylsulfatase were added and to 300 mL plasma,
1.7 mL sodium acetate buffer and 50 mL b-glucuronidase/arylsulfatase
were added. After overnight incubation at 37C, 4-hydroxybenzophe-
none was added as internal standard. The prenylflavonoids from urine
and feces samples were extracted in triplicate with ethyl acetate (4).
Plasma samples were extracted with ethyl acetate and hexane. To a 2-mL
sample, 3 mL water (pH 2), 5 mL ethyl acetate, and 1 mL hexane were
added. After vortexing and centrifugation (8000 3 g; 10 min), 4 mL
supernatant was collected. A second extraction was performed and 5 mL
supernatant was collected and pooled with the first extract. The extracts
were dried under nitrogen, then dissolved in 250 mL water/methanol
(1:1, v:v) with formic acid (0.025%, v:v).
Organs (2 g liver, 0.7 g kidney, 0.6 g brain, and 0.15 g uterus)
collected from each rat and extra organ samples from control rats
without IX supplementation were processed as reported elsewhere (18).
Using this protocol, ;85% of IX and 8-PN standards were recovered
when 1 mmol/L of each compound were added to the initial mixture.
Chemical analysis of SHIME samples and rat biological fluids and
tissues. Quantification of butyrate in the SHIME samples and rat cecal
contents was done as previously described (19). SHIME samples and
rat urine, feces, and plasma were analyzed for prenylflavonoids by
HPLC (4).
Organ samples were analyzed by liquid chromatography-tandemMS
(Agilent Technologies) using a reverse phase C18 LiChrospher column
(253 0.4 cm, 5 mm,Merck) according to Espı´n et al. (18) (Supplemental
Fig. 1). IX, 8-PN, and their corresponding metabolites were identified
according to their UV and MS spectra as well as tandem MS fragments.
The quantitation of the peaks was carried out by the selected ion-
monitoring mode. Due to the lack of both IX- and 8-PN-glucuronide
standards, the values for these metabolites were scored as high (111),
medium (11), low (1), and not detected (2). Not detected were those
that either did not permit the MS-MS fragmentation of the ion or the ion
intensity was below the background noise; low values were those that
permitted proper compound identification (mean integrated areas
;1 3 106); medium and high values exceeded the ion intensity of low
values by;2- to 5-fold (mean integrated areas;33 106) and 10- to 30-
fold (mean integrated areas ;2 3 107), respectively. For ion intensity
comparison, the ionization of the mass spectrometer was checked daily
using IX and 8-PN standards.
PCR-denaturing gradient gel electrophoresis fingerprinting of
fecal and cecal bacterial communities. DNA extraction of the fecal
and cecal samples was performed as previously described (15). The 16S
ribosomal RNA genes for all bacteria were amplified by PCR using the
primers PRBA338f and P518r (20), and a 40-bp GC clamp was added
to the forward primer. Denaturing gradient gel electrophoresis (DGGE)
was performed using the Bio-Rad D gene system with 8% (w:v)
polyacrylamide gels and denaturing gradients from 45 to 60% (15).
Principal components analysis (PCA) of the DGGE profiles was per-
formed using the BioNumerics software v2.0 (Applied Maths) and PCA
ordinations were calculated using the Pearson product-moment corre-
lation coefficient. Within each character set, this coefficient subtracts
each character from the mean and divides it by the variance of the
character set.
Real-time PCR quantification of E. limosum. A real-time PCR
protocol specific for E. limosum was developed based on the method of
Kageyama et al. (21). Amplification was performed with an ABI Prism
SDS 7000 instrument with the PCR Master Mix (23) SYBR Green kit
(Applied Biosystems). A total of 300 nmol/L of the primers LimoF
(TGG-ATC-CTT-CGG-GTG-ACA-TT) and LimoR (CTC-ATT-GGG-
TAC-CGT-CAT-TC) were used and the protocol consisted of 2 min at
50C; 10 min at 95C; 40 cycles of 30 s at 94C, 30 s at 63C and 30 s at
72C. Standard curves were constructed with cloned 16S ribosomal
RNA genes from E. limosum in a concentration range from log 16 to log
8 DNA copies per liter and DNA from at least 10 nontarget species was
used to test amplification specificity.
Statistical analyses. Values are expressed as means 6 SEM. Expt.
1 and Expt. 2 were analyzed as separate factorial studies, with bacterial
status (Hop 2 and Hop 1 in SHIME assays; GF, Hop –, and Hop 1 in
rat assays), intestinal segment (ascending, transverse, and descending
colon in SHIME assays; cecum and colon in in vitro incubations with
rat intestinal contents), and gender (male and female in rat assays) as
treatments. The effects of bacterial status and intestinal segment
(SHIME assays and in vitro incubations) or bacterial status and gender
(rat assays) were analyzed with 2-way ANOVA. Following significant
ANOVA, the Newman-Keuls test was used for pairwise comparisons. In
Expt. 2, E. limosum was administered to the same SHIME Hop – and
Hop 1 compartments as those used in Expt. 1. Similarly, in the rat
assays, one-half of the rats used in Expt. 1 for IX and 8-PN analysis in
urine and feces were further used in Expt. 2 for the same purpose.
Therefore, 8-PN production in the SHIME and IX and 8-PN excretion in
the rats with (Expt. 2) and without (Expt. 1) E. limosumwere compared
with ANOVA for repeated measurements. When data were not normally
distributed, nonparametric tests were used. The significance level was set
at P , 0.05. Calculations were performed with Statview software
(version 5.0, SAS Institute).
Results
Activation of IX into 8-PN by E. limosum in the Hop 1 and
Hop – SHIME model. Using the in vitro TWINSHIME setup,
the steady-state 8-PN production in each colon reactor in the
absence (Expt. 1) or presence (Expt. 2) of E. limosum was
quantified (Table 2). When only IX was dosed, no 8-PN
production occurred in the Hop – compartment inoculated with
intestinal microbiota derived from the Hop – individual. In
contrast, IX was partially converted in both the transverse and
descending colon reactors of the Hop 1 compartment, inocu-
lated with intestinal microbiota derived from the Hop 1 in-
dividual. When E. limosum was administered with IX, the 8-PN
production did not significantly increase in the Hop 1 compart-
ment compared with Expt. 1, whereas 8-PN production reached
40% in the descending colon reactor of the Hop – compartment.
In parallel, butyrate production increased compared with Expt.
1 in the ascending colon from both the Hop 1 and Hop –
compartments (data not shown), respectively, from 5.7 and 2.3
mmol/L to 10.8 and 4.5 mmol/L (P , 0.01).
Activation of IX into 8-PN by E. limosum in incubations of
the rats’ cecal and colonic contents. We assessed the ability
of the intestinal contents of the rats to produce 8-PN after in
vitro incubation of the cecal and colonic contents with IX (Table
2). In Expt. 1, the 8-PN production was highest for all the rats in
the contents derived from the Hop1 group. Only very low 8-PN
production was noted in the contents derived from the Hop –
rats and no 8-PN was produced in the incubation of the GF rat
contents. E. limosum administration to the rats (Expt. 2)
significantly increased 8-PN production in the cecal and colonic
contents derived from the Hop – group compared with Expt. 1,
but not in those from the Hop 1 group. The intestine of the GF
rats now contained only E. limosum, leading to 100% IX
conversion into 8-PN. Cecum and colon incubations did not
differ in any of the rat groups.
Excretion of IX and 8-PN in rat feces and urine. IX and 8-PN
were analyzed in the fecal and urinary outputs collected in the
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last 2 d of the dosing period of Expt. 1 and Expt. 2. Because the
daily excretion values were correlated (0.62 , r , 0.82; P ,
0.001), the mean excretion of the 2 d was used as the variable
(Fig. 1).
Without taking bacterial status into account, excretion of IX
in feces reached 263.56 40.2 nmol/d in Expt. 1 and decreased to
99.8 6 19.2 nmol/d in Expt. 2. In Expt. 1, 8-PN excretion was
negligible in GF rats and it was significantly higher in the urine of
the Hop 1 rats than in the Hop – rats. Consumption of E.
limosum (Expt. 2) increased the 8-PN excretion in the Hop – and
GF rats compared with Expt. 1 but did not influence the Hop 1
rats, resulting in similar excretions in all rats in the feces (294.16
132.2 nmol/d) and urine (8.5 6 1.1 nmol/d). No consistent
gender effects were observed (Supplemental Table 1).
The importance of liver phase II metabolism was assessed by
quantifying the amounts of IX and 8-PN recovered in the urine
and feces of the GF rats with or without b-glucuronidase/
arylsulfatase treatment of the samples prior to analysis (Table 3).
When the rats consumed E. limosum, a 35% increase (P ,
0.05) in butyrate was detected in the ceca of both Hop 1 and
Hop – rats compared with Expt. 1, increasing to levels of 3.6 and
3.7 mmol/g (data not shown). The ceca of GF rats contained 1.86
0.6 mmol butyrate/g after E. limosum treatment.
Concentrations of IX and 8-PN in rat plasma and different
organs. Plasma IX concentrations were similar for all rats and
reached, respectively, 0.63 6 0.05 and 0.54 6 0.05 mmol/L in
Expt. 1 and Expt. 2. In Expt. 1, no 8-PN was detected in the GF
rats’ plasma and 8-PN concentrations were significantly higher
in the Hop1 (2.466 1.02 mmol/L) than the Hop – rats (0.776
0.04 mmol/L). However, the ratio of 8-PN concentration to the
combined IX and 8-PN concentration was not significantly
higher in Hop1 rats than in Hop – rats (Fig. 1). After treatment
with E. limosum (Expt. 2), plasma 8-PN concentrations were
similar in all rats (1.71 6 0.23 mmol/L) and 8-PN ratios in the
GF rats’ plasma were even higher than in the HMA rats.
Plasma samples of the GF rats from Expt. 2 were investigated
for the presence of free aglycones and phase I and II liver
metabolites. Whereas low concentrations of aglycones were
detected, IX and 8-PN mainly circulated as phase II glucuro-
nides. Moreover, very low quantities of phase I metabolites with
the same molecular mass as IX- and 8-PN-alcohols were
detected.
No unconjugated IX or 8-PN was detected in any tissue. The
IX- and 8-PN-glucuronides were the only metabolites detected
(Table 4). Glucuronidase treatment of the tissue removed the
glucuronides, but the corresponding aglycones could not be
detected because these showed lower ionization than their cor-
responding glucuronides. IX-Glucuronide was detected in 97%
60, and 50% of liver, kidney, and uterus tissues, respectively.
In Expt. 1, 8-PN-glucuronides were detected in neither GF nor
Hop – rats, whereas they were detected in 85% of the Hop1 rats.
After E. limosum administration, 8-PN metabolites were de-
tected in all rats but with differences depending on the tissue: 89,
33, and 28% of liver, kidney, and uterus tissues, respectively. No
IX or 8-PN metabolites were detected in brain tissues.
E. limosum concentrations and bacterial community
composition. When only IX was dosed, the bacterium could
not be detected in either the SHIME or the rat cecal community
(Table 2). After administration to the TWINSHIME, E. limosum
was present in similar concentrations in all colon reactors of
both the Hop 1 and Hop – compartments. In Expt. 2 of the
rat trial, the cecal contents of the GF rats contained 2 to 3 log
higher concentrations than those of their Hop 1 and Hop –
counterparts.
PCA analysis of the microbial community profiles in the feces
of the Hop 1 and Hop – rats showed that the profiles grouped
based on their bacterial status (Fig. 2). Within 1 bacterial status,
the profiles grouped per 3, relating to the fact that the rats were
housed per 3. Whereas the DGGE profiles of the GF rats
contained no bands in Expt.1, 1 single band was present at the
end of Expt. 2, further confirming the presence of E. limosum.
TABLE 2 Conversion of IX into 8-PN and concentration of E. limosum in the colon compartments
of the SHIME and in in vitro incubations of rat cecum and colon contents1
Expt. 1 (IX) Expt. 2 (IX 1 E. limosum)
8-PN ratio2 E. limosum 8-PN ratio E. limosum
SHIME % log (DNA copies/g) % log (DNA copies/g)
Ascending colon Hop 1 0.0 6 0.0 n.d.3 0.0 6 0.0 7.77 6 3.95
Hop 2 0.0 6 0.0 n.d. 0.0 6 0.0 7.82 6 4.51
Transverse colon Hop 1 38.6 6 8.5a* n.d. 53.7 6 11.2a* 7.56 6 4.36
Hop 2 0.0 6 0.0b n.d. 0.0 6 0.0b 8.06 6 4.12
Descending colon Hop 1 78.4 6 5.7a1 n.d. 90.1 6 6.9a1 7.84 6 4.28
Hop 2 0.0 6 0.0b n.d. 40.2 6 2.4b*# 7.52 6 4.27
Rats
Cecum Hop 1 32.7 6 15.2a n.d. 54.6 6 10.7a 5.58 6 2.32a
Hop 2 2.7 6 1.2b n.d. 9.0 6 1.5b 6.48 6 2.65a
GF 0.0 6 0.0c n.d. 100.0 6 0.0c 8.95 6 3.65b
Colon Hop 1 38.4 6 16.1a / 44.3 6 9.9a /
Hop 2 1.6 6 0.9b / 28.9 6 15.3a /
GF 0.0 6 0.0c / 100.0 6 0.0b /
1 Values are means 6 SEM, n ¼ 6. Within each experiment and intestinal segment, means with superscripts without a common letter
differ; *,1, within each experiment and bacterial status, means with different symbols differ; #different from Expt. 1, P , 0.05.
2 8-PN ratio ¼ 8-PN/(IX18-PN) 3 100.
3 n.d., Not detected; /, not performed.
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Discussion
Until now, the application of probiotics has mainly been limited
to strains belonging to a few genera, such as bifidobacteria and
lactobacilli (22). However, the human gut is colonized by
hundreds of species and many perform important metabolic
reactions or exert biological activities that might translate into
clinical benefits (23). In this research, E. limosum is presented as
an important candidate probiotic because of its butyrate
production (13) and its specific metabolic potential to reduce
interindividual variability in hop phytoestrogen metabolism and
exposure.
Interindividual variation in phytoestrogen metabolism has
been reported by several authors (24,25) and was recently also
shown for hop phytoestrogens (3,4). As noted for isoflavones
and lignans (26), the results from this study also definitively
show the crucial role of the intestinal microbiota in the pro-
duction of 8-PN from IX.Whereas 8-PNwas not detected in any
of the biological samples from the GF rats after dosing IX,
colonization of the rats with fecal microbiota from subjects with
a high (Hop 1) or a low (Hop 2) 8-PN production status,
resulted in rats with different 8-PN production and excretion.
Similarly, inoculation of the TWINSHIME with these samples
resulted in an 8-PN–producing (Hop 1) and nonproducing
(Hop 2) compartment.
Moreover, a relation was found between the ability of the rat
intestinal contents to produce 8-PN from IX in vitro and the
8-PN recovery in rat excreta. Also, 8-PN was only detected in
organs of the Hop 1 rats after IX administration. This can be
considered as definitive evidence that differences in the intestinal
metabolic potential not only determine 8-PN production but
also 8-PN exposure after hop consumption.
As differences in phytoestrogen exposure due to differential
intestinal metabolism may hamper therapeutic applicability, E.
limosumwas used as probiotic to equilibrate the 8-PN exposure.
When only IX was administered to the TWINSHIME, 8-PN
production was observed in only the Hop 1 SHIME, with up to
80% conversion. After dosing the probiotic in the ascending
colon of both SHIME compartments, high bacterial concentra-
tions were detected in the colon regions, coinciding with 40%
8-PN production in the Hop – compartment. Moreover, the bu-
tyrate production in the ascending colon doubled, also leading to
increased butyrate concentrations in the rest of the intestine. The
survival of probiotics in the SHIME (19,27) has been tested
several times and recently the efficacy of a probiotic microbial
consortium to increase equol production was shown (28).
Similarly, the Hop1 rats produced muchmore 8-PN than did
the Hop – rats. Probiotic administration increased the IX
activation in the rat large intestine, as shown by the in vitro incu-
bations of the rat cecal and colonic contents. Molecular analysis
confirmed the efficacy of the treatment. E. limosum could be
recovered in all cecal samples, with the highest titers in the GF
rats, due to the lack of competition with indigenous bacteria in
these rats. After probiotic treatment, the 8-PN excretion in both
feces and urine was similar for all rats. Coincidentally, butyrate
concentrations also increased in the cecum of all rats. This shows
that the probiotic can survive the stomach and small intestinal
environment and equilibrates 8-PN exposure by increasing the
IX activation in low 8-PN producers to the levels found in high
producers. This is further confirmed by the fact that the
phytoestrogen was now detected in the organs of all rats.
Without taking bacterial status into account, the first 24-h
total prenylflavonoid excretion relative to the daily dose (2 mg/kg
body weight) reached 35.0 6 6.6% in the feces and 2.4 6 0.6%
in the urine. Although no pharmacokinetic data of IX are
available, these data correspond with the few available data on
8-PN excretion. After single oral administration of 50 mg to
postmenopausal women, 8-PN was excreted within 48 h in feces
FIGURE 1 Recovery of 8-PN in the feces (A), urine (B), and plasma
(C) of rats administered IX in the absence (Expt. 1, n ¼ 12) or presence
(Expt. 2, n ¼ 6) of E. limosum. Values are means 6 SEM, expressed
as the ratio of 8-PN concentration to the combined IX and 8-PN
concentration. Within each experiment, means without a common
letter differ; # different from Expt. 1, P , 0.05.
TABLE 3 Recovery of IX and 8-PN aglycones in urine and feces
of GF rats administered IX in the absence (Expt. 1)
or presence (Expt. 2) of E. limosum1
Urine Feces
IX 8-PN IX 8-PN
%
Expt. 1 (IX) 30.6 6 6.9 n.d.2 47.2 6 13.1 n.d.
Expt. 2 (IX 1 E. limosum) 32.9 6 7.2 45.8 6 7.2* 37.4 6 7.8* 68.8 6 9.7*
1 Values are means 6 SEM, n ¼ 6. *Different from Expt. 1, P , 0.05.
2 n.d., Not detected.
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and urine to levels of 23 and 8%, respectively (29). Plasma
concentrations were also well within the range of plasma 8-PN
concentrations (14.5 mmol/L) detected after 3-mo oral treatment
of 6.8 mg 8-PN/kg to rats (30).
GF rats are a good model to study enterohepatic circulation
of ingested compounds due to the absence of deconjugating
bacteria. The assessment of liver metabolites in the GF rat sam-
ples showed that there is enterohepatic circulation of prenyl-
flavonoids. Also, 53% IX-glucuronides were recovered from the
GF rat feces. This shows that a major part of IX is first absorbed
and then excreted back into the intestine by the liver, similar to
what happens with other flavonoids (31). However, in contrast
to the low urinary recovery of aglycones for most flavonoids
(32), 30% of IX excreted in urine in this research was composed
of aglycones and this increased to 46% for 8-PN. Whereas some
researchers have shown that the administration of flavonoids
through oral gavage may decrease phase II metabolism (32), an
alternative explanation is that the presence of the prenyl chain
limits phase II metabolism.
In conclusion, this work further indicates the important role
of intestinal bacteria in determining the final exposure to 8-PN
after consumption of IX-containing hop products. Whereas no
8-PN production was noted in the GF rats, higher 8-PN pro-
duction occurred in the Hop 1 intestinal model and rats
compared with the Hop – model and rats. In addition, orally
administered E. limosum reached the colon, increased the
butyrate production in the SHIME and rats, and increased the
8-PN production in the Hop – model and Hop – and GF rats. In
this way, the final exposure to hop phytoestrogens was modu-
lated by the probiotic, with similar 8-PN production in all HMA
rats.
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